Published in J Am Coll Cardiol on March 06, 2012
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25
Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol (2013) 1.00
Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012. Wien Klin Wochenschr (2012) 0.78
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med (2006) 6.00
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA (2002) 4.06
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS Biol (2007) 2.49
Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation (2005) 2.31
Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol (2006) 2.18
Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation (2006) 2.11
Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. Radiology (2014) 2.09
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation (2005) 1.97
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail (2011) 1.93
Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail (2010) 1.93
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Fibronectin forms the most extensible biological fibers displaying switchable force-exposed cryptic binding sites. Proc Natl Acad Sci U S A (2009) 1.77
Diastolic mitral annular velocity during the development of heart failure. J Am Coll Cardiol (2003) 1.76
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med (2004) 1.67
Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol (2011) 1.66
Evaluation of LV diastolic function from color M-mode echocardiography. JACC Cardiovasc Imaging (2011) 1.62
"Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2008) 1.61
Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol (2003) 1.60
The cardiovascular effects of erythropoietin. Cardiovasc Res (2003) 1.59
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail (2012) 1.54
Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol (2009) 1.50
Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005. J Invasive Cardiol (2007) 1.49
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail (2015) 1.49
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Restrictive left ventricular filling pattern does not result from increased left atrial pressure alone. Circulation (2008) 1.45
Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant (2007) 1.45
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Culprit vessel PCI versus traditional cath and PCI for STEMI. J Invasive Cardiol (2008) 1.44
Chronic heart failure: a report from the Dartmouth Diastole Discourses. Congest Heart Fail (2006) 1.44
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Loss of adrenergic augmentation of diastolic intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-mode echocardiography. JACC Cardiovasc Imaging (2012) 1.40
Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes. J Invasive Cardiol (2010) 1.39
Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol (2002) 1.38
Cardiac-specific expression and hypertrophic upregulation of the feline Na(+)-Ca(2+) exchanger gene H1-promoter in a transgenic mouse model. Circ Res (2002) 1.35
Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC Cardiovasc Interv (2008) 1.35
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail (2010) 1.29
Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol (2005) 1.28
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail (2008) 1.28
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest (2012) 1.25
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2011) 1.22
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J (2009) 1.19
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail (2010) 1.15
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Quantification of protein expression changes in the aging left ventricle of Rattus norvegicus. J Proteome Res (2009) 1.13
Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003. Catheter Cardiovasc Interv (2006) 1.11
Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation (2006) 1.10
Crosslinking of cell-derived 3D scaffolds up-regulates the stretching and unfolding of new extracellular matrix assembled by reseeded cells. Integr Biol (Camb) (2009) 1.08
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
Vortices formed on the mitral valve tips aid normal left ventricular filling. Ann Biomed Eng (2013) 1.06
Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation (2005) 1.06
Comments on Defining the Contribution of Diastolic Vortex Ring to Left Ventricular Filling. J Am Coll Cardiol (2015) 1.06
A multidimensional proteomic approach to identify hypertrophy-associated proteins. Proteomics (2006) 1.04
Assessment of left ventricular diastolic function and recognition of diastolic heart failure. Circulation (2007) 1.04
New molecular mechanism in diastolic heart failure. Circulation (2006) 1.02
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol (2006) 1.00
Can left ventricular diastolic stiffness be measured noninvasively? J Am Soc Echocardiogr (2002) 1.00
Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol (2008) 1.00
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res (2003) 1.00
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol (2002) 1.00
Feasibility to detect severe coronary artery stenoses with upright treadmill exercise magnetic resonance imaging. Am J Cardiol (2003) 0.99
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol (2004) 0.96
Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail (2014) 0.96
STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci (2008) 0.96
Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol (2004) 0.96
Contribution of right-sided heart enlargement to cardiomegaly on chest roentgenogram in diastolic and systolic heart failure. Am J Cardiol (2006) 0.96
Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg (2002) 0.95
Left ventricular vortex formation is unaffected by diastolic impairment. Am J Physiol Heart Circ Physiol (2012) 0.95
A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. Am J Physiol Heart Circ Physiol (2008) 0.95
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2012) 0.94
Contribution of systolic and diastolic abnormalities to heart failure with a normal and a reduced ejection fraction. Prog Cardiovasc Dis (2006) 0.93
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation (2005) 0.93
In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol (2008) 0.93
Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. Am J Physiol Heart Circ Physiol (2003) 0.93
Incidence of coronary stent thrombosis based on academic research consortium definitions. Am J Cardiol (2008) 0.93
Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol (2007) 0.92
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload. J Mol Cell Cardiol (2007) 0.91
Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol (2005) 0.90
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail (2014) 0.90